Combinations of fluoropyrimidines with oxaliplatin or irinotecan plus a biologic agent are
standard treatments for metastatic colorectal cancer (mCRC). Recent approvals of first-line …

Importance The EGFR inhibitors (EGFR-I) cetuximab and panitumumab and the
angiogenesis inhibitors (AIs) bevacizumab and aflibercept have demonstrated varying …

The treatment of colorectal cancer has become increasingly complex over recent years. With
the emergence of new chemotherapy drugs and targeted agents, there has been great …

The treatment of metastatic colorectal cancer (mCRC) has evolved significantly over the past
10 years. For nearly 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) was the only agent …

The emergence of targeted therapies for the treatment of metastatic colorectal cancer
(mCRC) has considerably improved survival, but has also resulted in a dilemma of …

There has been an intensive effort to develop novel therapies for the treatment of metastatic
colorectal cancer (mCRC). The anti‐epidermal growth factor receptor (EGFR) antibodies …

More therapeutic options are now available than ever before for patients with metastatic
colorectal cancer (mCRC) and, as such, treatment decisions have become more complex. A …

Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve
response rate and prolong median survival over fluorouracil with leucovorin (FU/LV), and …

Metastatic colorectal cancer is a significant cause of morbidity and mortality in the US and
around the world. While several novel cytotoxic and biologic therapies have been …

First-line therapy for metastatic colorectal cancer (mCRC) with fluorouracil plus folinic acid in
combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is an established standard of …